Company intelligence / Profile preview
Suzhou Junjing Biomedical Technology
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Junjing Biomedical Technology is a jointly-invested company by Junshi Biosciences and Wigen Biomedicine, primarily developing JS110, an XPO1 inhibitor that received FDA IND approval in 2022 and is in early-stage clinical development.[5][6][7][9]
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Junshi BiosciencesWigen Biomedicine Technology
Beyond the preview
Go deeper on Suzhou Junjing Biomedical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Junjing Biomedical Technology.